# Nephrology Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Jack London (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET010-SYN-TD
- Date: 1915-08-18
- Fictional facility: St. Posthumous Health Center
- Fictional author: Teodor Mbatha-Rasmussen, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Requested by: Eleanor Whitcombe-Ibe, MD

## Reason for consultation

Reduced kidney function (creatinine 1.98 mg/dL, eGFR 43) with albumin in the urine (240 mg/g) and untreated high blood pressure (158/98) in a 39-year-old writer with severe alcohol use disorder, who has taken naproxen most days for two years. Please confirm the stage and cause, and advise on blood pressure, an SGLT2 inhibitor, medicine for his alcohol use disorder at this kidney function, and pain relief. **S**

## History

Mr. London, 39, a novelist who writes every morning on his ranch, is seen at the request of Dr. Whitcombe-Ibe two weeks after reduced kidney function, albumin in the urine and high blood pressure were found, together with severe alcohol use disorder. He stopped drinking the day after the intake visit and completed a five-day chlordiazepoxide taper without complications; he has had no alcohol for twelve days. He stopped naproxen and takes acetaminophen. He has taken losartan 50 mg for two weeks without dizziness. He has never passed a stone or had gout, blood in the urine or a rash. He remembers being told years ago that his kidneys were damaged, at an operation for his appendix. **S**

## Examination

| System | Finding |
|---|---|
| General | Well; blood pressure 146/92, pulse 84; weight 83.6 kg |
| Cardiovascular | Regular rhythm; no murmur or bruit; trace ankle edema |
| Skin | No rash, purpura or tophi |
| Neurological | No tremor |

BP 146/92 mmHg; pulse 84 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 83.6 kg; BMI 27.9 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Whitcombe-Ibe's intake note and results: creatinine 1.98 mg/dL, eGFR 43, urine albumin-to-creatinine ratio 240 mg/g, uric acid 8.4 mg/dL, PTH 74 pg/mL, hemoglobin 13.6 g/dL, AST 68, ALT 41, GGT 186 U/L, FIB-4 2.28, PEth 410 ng/mL, HbA1c 5.4%. Urinalysis: 2+ protein, no blood, no casts or crystals. Insurance examination report: creatinine 1.7 mg/dL about fourteen months ago. Today: potassium 4.9 mmol/L, creatinine 2.04 mg/dL (eGFR 42), AST 49, ALT 36, GGT 141 U/L. Ultrasound this morning: kidneys 10.8 and 11.0 cm, echogenic, no stones, hydronephrosis or cysts; fatty liver; normal spleen. Elastography: liver stiffness 7.2 kPa, controlled attenuation parameter 312 dB/m. Kidney failure risk equation: five-year risk about 5 percent, two-year about 1.5 percent. Estimated creatinine clearance (Cockcroft-Gault) about 58 mL/min. Potassium: 4.9 mmol/L; Creatinine: 2.04 mg/dL (high); eGFR (CKD-EPI 1910): 42 mL/min/1.73 m² (low); AST: 49 U/L (high); ALT: 36 U/L; GGT: 141 U/L (high). All results are synthetic.

## Assessment

1. **Chronic kidney disease G3b A2** (N18.32). Chronic kidney disease, stage G3b A2 by KDIGO 1913: an eGFR of 42 to 43 with albumin 240 mg/g, and a creatinine already 1.7 mg/dL fourteen months ago, so it has lasted more than three months; high risk on the KDIGO heat map. Normal-sized echogenic kidneys, a bland sediment without blood, moderate rather than heavy albuminuria and long-standing untreated hypertension point to hypertensive kidney disease, with two years of daily naproxen adding harm. There are no stones or obstruction, and no gout attacks; the uric acid of 8.4 mg/dL does not need treatment without gout. Alcohol raises blood pressure but is not itself a usual cause of this picture. Nothing suggests a glomerulonephritis or another disease that needs a biopsy now; hepatitis B, hepatitis C and HIV serology are drawn today, and a biopsy would be reconsidered for blood in the urine, rising albumin or a fall in eGFR without explanation. A cystatin C estimate is not needed now, since no decision hinges on it. 25-hydroxyvitamin D was not drawn and should be. **S**
2. **Blood pressure** (I12.9). Aim for a systolic below 120 by standardized office measurement if he tolerates it, as KDIGO 1910 advises, and at least below 130/80 as the 1914 AHA/ACC guideline does. Losartan should go to the maximum tolerated dose, 100 mg, because it lowers albuminuria as well as pressure; potassium 4.9 and a 3 percent rise in creatinine are acceptable. Check potassium and creatinine two to four weeks after each change; accept a creatinine rise of up to 30 percent. Less than 2 g of sodium a day; amlodipine would be the next step. **S**
3. **SGLT2 inhibitor** (N18.32). He meets the KDIGO 1913 recommendation for an SGLT2 inhibitor (eGFR 20 or more with albumin 200 mg/g or more), which slows kidney decline whether or not there is diabetes. But heavy drinking, missed meals and vomiting raise the risk of ketoacidosis on these drugs, even without diabetes. I advise waiting until he has been abstinent for some weeks and is eating regularly, then dapagliflozin 10 mg daily with written sick-day rules, and potassium and creatinine two to four weeks after starting, expecting an early dip in eGFR. **S**
4. **Medicine for alcohol use disorder** (F10.20). Naltrexone is the better choice. It is cleared mainly by the liver, needs no dose change at his kidney function, and his liver tests are falling and under three times normal; he takes no opioids. Acamprosate is cleared by the kidneys: at a creatinine clearance of 30 to 50 mL/min the dose must be cut to 333 mg three times a day and below 30 it should not be used, and with his clearance near 58 and likely to change, and a three-times-a-day schedule he says he would not keep, it is a second choice. The outpatient chlordiazepoxide taper was reasonable for his kidneys, since it is cleared by the liver, and safe for a liver without cirrhosis; in a man with cirrhosis or worse liver function a shorter-acting benzodiazepine would be preferred. Disulfiram is not advised. **S**
5. **Pain relief** (Z79.1). No naproxen, ibuprofen, high-dose aspirin or other oral anti-inflammatory medicines, which cut kidney blood flow and caused part of this damage. Acetaminophen is the first choice, kept to 2,000 mg a day after heavy drinking. A short course of a topical anti-inflammatory gel on a small area is acceptable, because blood levels are low. No opioids or tramadol: naltrexone blocks opioids, morphine's active products build up when the kidneys are weak, and opioids add risk in early recovery. Any new medicine should be checked for kidney dosing, and iodinated contrast used only with precautions. **S**

## Recommendations

1. Chronic kidney disease G3b A2, most likely hypertensive with naproxen contributing; no biopsy now; hepatitis B, hepatitis C and HIV serology today; 25-hydroxyvitamin D with the next blood test.
2. Losartan raised to 100 mg at about six weeks if potassium allows, with potassium and creatinine two to four weeks after each change; systolic target below 120 if tolerated; sodium below 2 g a day; amlodipine next if needed.
3. Dapagliflozin 10 mg daily once he has been abstinent for some weeks and is eating regularly, with written sick-day rules and potassium and creatinine two to four weeks later.
4. Naltrexone 50 mg daily, with a wallet card and liver tests at four to six weeks; acamprosate only as a second choice at a reduced dose, and not below a creatinine clearance of 30.
5. No oral NSAIDs, no opioids or tramadol; acetaminophen up to 2,000 mg a day; topical gels for short courses only.
6. Creatinine, eGFR and urine albumin twice a year once stable; calcium, phosphate and PTH every six to twelve months; hemoglobin yearly; no statin now at 39 without diabetes or heart disease; no treatment for the uric acid without gout.
7. Pneumococcal, influenza, hepatitis B and COVID-19 vaccines.

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Communication

Discussed with Dr. Whitcombe-Ibe, who saw him the same day. Mr. London asked plainly whether his kidneys would fail. He was told that his kidneys have lost about half their filtering, that the five-year risk of needing dialysis is about one in twenty, and that stopping alcohol and naproxen, controlling blood pressure and the two kidney-protecting medicines can slow or halt the decline. He chose naltrexone and agreed to wait for dapagliflozin. **S**

## Follow-up

Dr. Whitcombe-Ibe continues care at six, ten and twelve weeks; nephrology review in three months, or sooner for potassium above 5.5 mmol/L, a creatinine rise of more than 30 percent, blood in the urine, or rising albumin. **S**

## Guideline basis

- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024), Kidney Disease: Improving Global Outcomes (Kidney Int 2024;105(4S):S117-S314)
- KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021), Kidney Disease: Improving Global Outcomes (Kidney International)
- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (Circulation 2025;152(11):e114-e218)
- CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension and depression monographs (2026), Aether Forge
- The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018), American Psychiatric Association (Am J Psychiatry 2018;175(1):86-90)
- VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021), United States Department of Veterans Affairs and Department of Defense
- The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020), American Society of Addiction Medicine (Journal of Addiction Medicine)
